Table 2.
Characteristics of response (n = 48) and nonresponse (n = 20) depressive patients to antidepressant treatment
| Characteristics | Patients (%) | P‐value | |
|---|---|---|---|
| Response | Nonresponse | ||
| Age, median (Q1–Q3), years | 65.0 (62.0–69.3) | 64.0 (58.5–71.0) | 0.439b |
| Sex, M:F | 12:36 | 4:16 | 0.762b |
| BMI, median (Q1–Q3) | 23.8 (22.3–26.0) | 24.4 (22.7–27.3) | 0.369c |
| Onset age, median (Q1–Q3), years | 59.5 (50.0–65.3) | 57.5 (50.0–61.5) | 0.839c |
| Episodes of MDD, median (Q1–Q3) | 2 (1–3) | 2 (1–2) | 0.390c |
| Antidepressant used | |||
| Fluoxetine | 25 (52.1) | 12 (60.0) | 0.602b |
| Othersa | 23 (47.9) | 8 (40.0) | |
| HAM–D score at baseline, median (Q1–Q3) | 18.5 (17.0–21.0) | 21.0 (19.0–22.3) | 0.033c |
| Family history | 11 (22.9) | 2 (10.0) | 0.317c |
| Comorbid conditions | |||
| Hypertension | 17 (35.4) | 7 (35.0) | 1.000b |
| Diabetes | 9 (18.8) | 4 (20.0) | 1.000b |
| Hyperlipidemia | 2 (4.2) | 0 (0.0) | 1.000b |
Q1, lower quartile; Q3, upper quartile; BMI, body mass index; MDD, major depressive disorder; HAM‐D, Hamilton rating scale for depression. aSSRIs including paroxetine, escitalopram, and sertraline. b P‐values from Fisher's exact test. c P‐values from Wilcoxon rank‐sum test.